To determine if primary, patient-derived B-ALL cells are similarly dependent on RUNX1 in vivo, we transduced two clinically aggressive pediatric B-ALL patient samples with the two most effective RUNX1 shRNAs and engrafted them into NSG mice (Supplementary Table 3, see “Methods”). This evidence concerns the gene RUNX1 and precursor B-cell acute lymphoblastic leukemia.